USAN drug names under consideration

USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more.

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: USAN@ama-assn.org. 

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

Comtifator: Treatment of Central Nervous System (CNS) disorders, including neurodegenerative disease such as Alzheimer's disease 

Copper 64CU zadavotide guraxetan: Indicated for use with positron emission tomography (PET) for detection of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer

Efpixileukin alfa: Treatment of atopic dermatitis and psoriasis   

Farabursen: Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Farabursen sodium: Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Irafamdastat: Treatment of conditions where increasing endocannabinoid tone is beneficial  

Marlotamig: Antineoplastic, treatment of solid tumors

Milsaperidone: Treatment of schizophrenia, bipolar disorder, and major depressive disorder

Moponebart: Treatment endometriosis related pain  

Nilotinib D-Tartrate: Antineoplastic 

Ordastobart: Antineoplastic 

Patent Blue: Oncology imaging agent

Patent Blue sodium: Oncology imaging agent

Pentagalloylglucose: Stabilization and protection of elastin and collagen from enzymatic degradation

Piperaquine: Antimalarial

Piperaquine phosphate: Antimalarial

Polfermetinib: Antineoplastic 

Prulacabtagene leucel: Antineoplastic; Treatment of Non-Hodgkin lymphoma or other B cell malignancies; Treatment of Autoimmune diseases 

Repibresib: Treatment of vitiligo 

Sevabertinib: Antineoplastic 

Simepdekinra: Treatment of interleukin 17 (IL-17) mediated diseases

Sturlimogene erparepvec: Antineoplastic

Tagmokitug: Antineoplastic

Tolododekin alfa: Antineoplastic

Trosunilimab: Treatment of HIV infection

Zervimesine: Treatment of Alzheimer's disease and Dementia with Lewy bodies

Ateganosine: Antineoplastic

Atigotatug: Treatment of small cell lung carcinoma (SCLC) 

Atumelnant: Treatment of diseases of the adrenocorticotropic hormone (ACTH), melanocortin receptor antagonists  

Atumelant maleate: Treatment of diseases of the adrenocorticotropic hormone (ACTH), melanocortin receptor antagonists  

Duvalgagene otiparvovec: Treatment of Fabry Disease 

Ebribafusp alfa: Antineoplastic

Envuretcel: Treatment of Geographic Atrophy (GA), secondary to dry Age Related Macular Degeneration (AMD)  

Gemlapodect: Treatment of Tourette Syndrome

Letetresgene autoleucel: Antineoplastic

Linustedastat: Treatment endometriosis related pain

Neladalkib: Treatment of non-small cell lung cancer (NSCLC) and solid tumors harboring ALK rearrangement or activating ALK mutation 

Ofirnolast: Treatment of inflammatory conditions

Pilavapadin: Treatment of neuropathic pain including diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PN)

Pilavapadin phosphate: Treatment of neuropathic pain including diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PN)

Plosaracetam: Treatment of dementia of the Alzheimer’s type

Serplulimab: Antineoplastic 

Solrikitug: Treatment of immunologic conditions

Surzetoclax: Treatment of multiple myeloma   

Usilnetug: Treatment of Alzheimer’s disease 

Zerlasiran: Treatment of Lp(a)-mediated cardiovascular disease

Zerlasiran sodium: Treatment of Lp(a)-mediated cardiovascular disease 

Zifogaptide: Acute and chronic wound healing

Zifogaptide acetate: Acute and chronic wound healing

Zimislecel: Treatment of Type 1 Diabetes

Abefolastat tesaroxetan: Treatment of PSMA (prostate-specific membrane antigen) targeting chelator for diagnosis and treatment of prostate cancer

Clemizole: Treatment of convulsions in Dravet syndrome and Lennox-Gastaut syndrome 

Clemisole hcl: Treatment of convulsions in Dravet syndrome and Lennox-Gastaut syndrome 

Fosigotifator: Treatment of vanishing white matter (VWM) disease, amyotrophic lateral sclerosis (ALS) and major depressive disorder (MDD) 

Fosigotifator sodium tromethamine: Treatment of vanishing white matter (VWM) disease, amyotrophic lateral sclerosis (ALS) and major depressive disorder (MDD)

Gotistobart: Treatment of cancer  

Ifinatamab: Antineoplastic

Ifinatamab deruxtecan: Antineoplastic

Lerodalcibep: Treatment of hypercholesterolemia 

Lunsekimig: Treatment of asthma and inflammatory diseases

Nelmastobart: Antineoplastic

Nolavetbart: Treatment of canine atopic dermatitis

Pegriseprument: Prevention of kidney transplant rejection, in combination with other immunosuppressants 

Pozedeutinurad: Chronic management of hyperuricemia in patients with gout

Raludotatug deruxetcan: Antineoplastic

Raludotatug: Antineoplastic

Tilatamig: Antineoplastic

Tilatamig samtotecan: Antineoplastic

Ucasareotide dasaroxetan: SSTR2 targeting chelator for diagnosis and treatment of SSTR2-positive tumors

Vosilasarn: Treatment of estrogen receptor (ER) and androgen receptor (AR)-positive breast cancer

Zalfermin: Treatment of metabolic-associated steatohepatitis (MASH)

Zipalertinib: Antineoplastic